Animals in Research: The Pharma Perspective

August 15, 2009

Derek Lowe of In the Pipeline has a post up on the use of animals in research within the drug company milieu. It is worth a read.

We watch with all the tools of our trade – remote-control physiological radio transmitters, motion-sensing software hooked up to video cameras, sensitive mass spectrometry analysis of blood, of urine, and whatever else, painstaking microscopic inspection of tissue samples, whatever we can bring to bear. But in the end, it all comes down to dosing animals and waiting to see what happens. That principle hasn’t changed in decades, just the technology we use to do it.

Now, if you don’t read Lowe that regularly you might want to skim through a few recent posts and you are almost inevitably going to run up against his formulation of the “90%” problem. His most recent musings on this topic concern convincing the (health-care reform engaged and politicizing) public that making effective medications is really hard stuff and the evul BigPharma companies work their tails off on the development side to get to drugs which can be marketed. All joking aside, I think his point is that 90% of drugs fail…at multiple levels of the development process!
This consideration I find critical for some aspects of the animals-in-research discussion.

Back to the original post I linked, we recognize that within BigPharma the toxicity testing is a hugely important part of medication development.

But we also give the drug candidates to healthy ones, at higher doses and for longer periods of time, in order to see what else the compounds might do that we don’t expect. Most of those effects are bad – I’d casually estimate 99% of the time, anyway – and many of them will stop a drug candidate from ever being developed. The more severe the toxic effect, the greater the chance that it’s based on some fundamental mechanism that will be common to all animals. In some cases we can identify what’s causing the trouble, once we’ve seen it, and once in a great while we can use that information to argue that we can keep going, that humans wouldn’t be at the same risk. But this is very rare – we generally don’t know enough to make a persuasive case. If your compound kills mice or kills rats, your compound is dead, too.
I’ve lost count of the number of compounds I’ve worked on that have been pulled due to toxicity concerns; suffice it to say that it’s a very common thing. Every time it’s been something different, and it’s often not for any of the reasons I feared beforehand. I’ve often said here that if you don’t hold your breath when your drug candidate goes into its first two-week tox testing, then you haven’t been doing this stuff long enough.

“Testing”, as opposed to “research” can sometimes be easier for ARA types to attack and indeed they work very hard to conflate cosmetics testing with all animal use, both testing and research. Since we academic types don’t really do “testing” quite so much we don’t have the best perspective to argue why, for example, toxicity testing of promising new compounds is so important and how it works.
This is why Derek Lowe’s comments are important. It is only from within the drug-development perspective that we can obtain these numbers about just how many compounds have been found very promising at the non-animal stages and how many have been ruled out at the non-animal stages. Ultimately it is important to communicate what proportion of highly promising candidates based on stage N-1 data/rationale are ruled out by Stage N. And just how many stages of screening (for 90% hit rate?) come before anything gets tested in an animal.
It might be of further interest to examine the proportion of compounds which are ruled out by the animal toxicity (and efficacy) testing . This is because one of the favorite lies of the ARA wackaloon perspective is to argue that if drugs continue to look promising after animal tests but ultimately end up failing in clinical trials this proves that animal research is ineffectual. This is wrong because if animal research prevents 90 drugs which would have been toxic or ineffective in human trials, identifies 8 as safe/effective which fail in humans and only 2 which end up clinical successes, this sounds pretty dang effective to me. The ARA perspective claims 80% failure for this scenario. In fact, an interpretation of 92% successful deployment* of animal models is more accurate.
From what I can tell, my numbers here are wildly optimistic. Fractions of a percent of compounds end up as human therapies. But these data are hard to come by. Why?
Because BigPharma is motivated to look successful, not to advertise their failures. So I’ve only seen reference to the failure rate in odd bits and drabs of talking with Pharma scientists like Derek Lowe. It would be nice if some of these Pharma companies started to understand that they could help communicate the necessity and value of animal experiments if they were a bit more open about the failure numbers.
[h/t: Abel Pharmboy]
*admittedly this overlooks the miss rate- the proportion of drugs found toxic or ineffective in animal models that would have been perfectly good drugs in humans. I don’t know how we could possibly estimate this number.

No Responses Yet to “Animals in Research: The Pharma Perspective”

  1. I’ve found that there is hardly any communication of the real ‘failure numbers’ internally, much less to the scientific community at large. Keeping the failure rate unknown (or at best, vague) perpetuates the subconscious delusion for all the hard-working, deadline-driven scientists in the company that their project is the only one failing, so they should certainly be doing more/better to make it work. This is obviously not intentional but a nifty side-effect.
    It doesn’t seem that the explanation that “Science is hard, and often doesn’t work” will be enough to convince any of the wackaloons that animal research & testing is necessary and important.


  2. DrugMonkey Says:

    Keeping the failure rate unknown (or at best, vague) perpetuates the subconscious delusion for all the hard-working, deadline-driven scientists in the company that their project is the only one failing
    I heard a BigPharma veteran claim at one point that only half of the people in PharmCo will ever, in their career, work on a marketed product. sound true? or wild hyperbole?


  3. DrZZ Says:

    The 90% failure rate is for compounds that make it into clinical trials. Those compounds have already had lots of very encouraging data and nothing terrible turn up in tox testing. If you go back to compounds that look good in some in vitro assay, it is a much, much higher failure rate.

    You also might want to take a look an an earlier post on that blog that points to a study which suggests that most of the clincal failures these days is not due to unexpected toxcity, but lack of efficacy. It suggests that we know enough about biology and animal models to weed out compounds that do really bad things, but we don’t know near enough to identify what does good things.


  4. Allyson Says:

    Terrific post and excellent information on the unseen numbers of compounds that appear promising in non-animal testing but would actually be harmful if delivered to humans. This point is absolutely overlooked.


  5. I heard a BigPharma veteran claim at one point that only half of the people in PharmCo will ever, in their career, work on a marketed product. sound true? or wild hyperbole?
    DM, if you are talking about biologists in BigPharma, I would say that is probably a gross underestimate for two big reasons. One: the 90% failure rate Derek Lowe mentions (which is probably approximately accurate) would suggest most people aren’t going to ever work on something that makes it into people. Two: the timeframe from target identification to anything remotely clinical is probably greater than the rate of turnover of biologists in pharma.


  6. juniorprof Says:

    While I don’t work in BigPharma, we work with them enough to have a good idea about these numbers and I agree with DGT that the half number is probably a gross underestimate. In fact, of the dozens of people I know in the industry I can only think of one team off the top of my head that has taken something into the clinic. So my experience would give a much lower number as well. DGTs second factor is also a very important one and for us neuroscientists it seems that turnover in the neuroscience area is especially high right now.


  7. lil mikey Says:

    Great post. I’ve blogged about it on my blog, the AR101 blog. Good arguments.


  8. fonteine Says:

    Perhaps an useful resources for people looking for alternatives ….


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: